Serrapeptáza

Pôsobí: protizápalovo, antioxidačne

Serrapeptáza je inzým, ktorý sa získava z larvy priadky morušovaj. Má protizápalové účinky a môže pôsobiť ako prevencia proti tvorbe krvných zrazenín, ale tieto účinky sú nespoľahlivé.

Užívanie

Štandardná dávka serrapeptázy je 10-60 mg. Mala by sa užívať 3x denne na prázdny žalúdok, to znamená 30 minút pred jedlom alebo 2 hodiny po jedle. Väčšina výskumov používa dávkovanie 10 mg každých 8 hodín. Na stanovenie optimálnej dávky bude potrebných viac výskumov na ľuďoch. 10 mg je približne ekvivalentných 20 000 enzymatickým jednotkám.

Medicínske upozornenie!

Literatúra

  1. Al-Khateeb TH, Nusair Y. Effect of the proteolytic enzyme serrapeptase on swelling, pain and trismus after surgical extraction of mandibular third molars. Int J Oral Maxillofac Surg. (2008)
  2. Bhagat S, Agarwal M, Roy V. Serratiopeptidase: a systematic review of the existing evidence. Int J Surg. (2013)
  3. Badhe RV, et al. Media optimization studies for Serratiopeptidase production from Serratia marcescens ATCC 13880. Hindustan Antibiot Bull. (2009)
  4. Purification and characterization of four proteases from a clinical isolate of Serratia marcescens kums 3958.
  5. Pansuriya R, Singhal R. Effects of dissolved oxygen and agitation on production of serratiopeptidase by Serratia marcescens NRRL B-23112 in stirred tank bioreactor and its kinetic modeling. J Microbiol Biotechnol. (2011)
  6. CASTANEDA-AGULLO M. Studies on the biosynthesis of extracellular proteases by bacteria. I. Serratia marcescens, synthetic and gelatin media. J Gen Physiol. (1956)
  7. Bromke BJ, Hammel JM. Regulation of extracellular protease formation by Serratia marcescens. Can J Microbiol. (1979)
  8. Matsumoto K, et al. Purification and characterization of four proteases from a clinical isolate of Serratia marcescens kums 3958. J Bacteriol. (1984)
  9. Selan L, et al. Proteolytic enzymes: a new treatment strategy for prosthetic infections. Antimicrob Agents Chemother. (1993)
  10. Cloning and sequencing of Serratia protease gene.
  11. Easily absorbable enzyme preparation.
  12. Umashankar MS, Sachdeva RK, Gulati M. Aquasomes: a promising carrier for peptides and protein delivery. Nanomedicine. (2010)
  13. Rawat M, et al. Development and in vitro evaluation of alginate gel-encapsulated, chitosan-coated ceramic nanocores for oral delivery of enzyme. Drug Dev Ind Pharm. (2008)
  14. Moriya N, et al. Intestinal absorption of serrapeptase (TSP) in rats. Biotechnol Appl Biochem. (1994)
  15. Woodley JF. Enzymatic barriers for GI peptide and protein delivery. Crit Rev Ther Drug Carrier Syst. (1994)
  16. KV S, Devi GS, Mathew ST. Liposomal formulations of serratiopeptidase: in vitro studies using PAMPA and Caco-2 models. Mol Pharm. (2008)
  17. Camenisch G, Folkers G, van de Waterbeemd H. Shapes of membrane permeability-lipophilicity curves: extension of theoretical models with an aqueous pore pathway. Eur J Pharm Sci. (1998)
  18. Obata K, et al. Prediction of oral drug absorption in humans by theoretical passive absorption model. Int J Pharm. (2005)
  19. Nirale NM, Menon MD. Topical formulations of serratiopeptidase: development and pharmacodynamic evaluation. Indian J Pharm Sci. (2010)
  20. Shah MH, Paradkar A. Cubic liquid crystalline glyceryl monooleate matrices for oral delivery of enzyme. Int J Pharm. (2005)
  21. Kakinuma A, et al. Repression of fibrinolysis in scalded rats by administration of Serratia protease. Biochem Pharmacol. (1982)
  22. Kee WH, et al. The treatment of breast engorgement with Serrapeptase (Danzen): a randomised double-blind controlled trial. Singapore Med J. (1989)
  23. Malshe PC. A preliminary trial of serratiopeptidase in patients with carpal tunnel Syndrome. J Assoc Physicians India. (2000)
  24. Jadav SP, et al. Comparison of anti-inflammatory activity of serratiopeptidase and diclofenac in albino rats. J Pharmacol Pharmacother. (2010)
  25. Tachibana M, et al. A multi-centre, double-blind study of serrapeptase versus placebo in post-antrotomy buccal swelling. Pharmatherapeutica. (1984)
  26. Chopra D, et al. A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of paracetamol, serratiopeptidase, ibuprofen and betamethasone using the dental impaction pain model. Int J Oral Maxillofac Surg. (2009)
  27. Murugesan K, Sreekumar K, Sabapathy B. Comparison of the roles of serratiopeptidase and dexamethasone in the control of inflammation and trismus following impacted third molar surgery. Indian J Dent Res. (2012)
  28. Panagariya A, Sharma AK. A preliminary trial of serratiopeptidase in patients with carpal tunnel syndrome. J Assoc Physicians India. (1999)
  29. Esch PM, Gerngross H, Fabian A. Reduction of postoperative swelling. Objective measurement of swelling of the upper ankle joint in treatment with serrapeptase– a prospective study. Fortschr Med. (1989)
  30. Bracale G, Selvetella L. Clinical study of the efficacy of and tolerance to seaprose S in inflammatory venous disease. Controlled study versus serratio-peptidase. Minerva Cardioangiol. (1996)
  31. Relevant Role of Fibronectin-Binding Proteins in Staphylococcus aureus Biofilm-Associated Foreign-Body Infections.
  32. Christner M, et al. The giant extracellular matrix-binding protein of Staphylococcus epidermidis mediates biofilm accumulation and attachment to fibronectin. Mol Microbiol. (2010)
  33. Kaplan JB. Biofilm dispersal: mechanisms, clinical implications, and potential therapeutic uses. J Dent Res. (2010)
  34. Artini M, et al. Comparison of the action of different proteases on virulence properties related to the staphylococcal surface. J Appl Microbiol. (2013)
  35. Artini M, et al. A new anti-infective strategy to reduce adhesion-mediated virulence in Staphylococcus aureus affecting surface proteins. Int J Immunopathol Pharmacol. (2011)
  36. Longhi C, et al. Protease treatment affects both invasion ability and biofilm formation in Listeria monocytogenes. Microb Pathog. (2008)
  37. Influence of interfaces on microbial activity.
  38. Costerton JW, et al. Bacterial biofilms in nature and disease. Annu Rev Microbiol. (1987)
  39. Lee HS, et al. A technique for quantitative cytology of nasal secretions. Eur Arch Otorhinolaryngol. (1991)
  40. Nakamura S, et al. Effect of the proteolytic enzyme serrapeptase in patients with chronic airway disease. Respirology. (2003)
  41. Majima Y, et al. Effects of orally administered drugs on dynamic viscoelasticity of human nasal mucus. Am Rev Respir Dis. (1990)
  42. Majima Y, et al. The effect of an orally administered proteolytic enzyme on the elasticity and viscosity of nasal mucus. Arch Otorhinolaryngol. (1988)
  43. Shimura S, et al. Effect of expectorants on relaxation behavior of sputum viscoelasticity in vivo. Biorheology. (1983)
  44. Mecikoglu M, et al. The effect of proteolytic enzyme serratiopeptidase in the treatment of experimental implant-related infection. J Bone Joint Surg Am. (2006)
  45. Ishihara Y, Kitamura S, Takaku F. Experimental studies on distribution of cefotiam, a new beta-lactam antibiotic, in the lung and trachea of rabbits. II. Combined effects with serratiopeptidase. Jpn J Antibiot. (1983)
  46. Aratani H, Tateishi H, Negita S. Studies on the distributions of antibiotics in the oral tissues: Experimental staphylococcal infection in rats, and effect of serratiopeptidase on the distributions of antibiotics (author’s transl). Jpn J Antibiot. (1980)
  47. Viswanatha Swamy AH, Patil PA. Effect of some clinically used proteolytic enzymes on inflammation in rats. Indian J Pharm Sci. (2008)
  48. Shimizu H, et al. A case of serratiopeptidase-induced subepidermal bullous dermatosis. Br J Dermatol. (1999)
  49. Mazzone A, et al. Evaluation of Serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double-blind, randomized trial versus placebo. J Int Med Res. (1990)